BeOne Medicines Ltd.
- ONC ยท Nasdaq
- Pharmaceutical Preparations
- Basel, Switzerland
- 12,000 employees
- CIK 0001651308
Updated from SEC filings through
Top things to know
Executives
-
John Oyler Chief Executive Officer 4, 2026-08-12 -
Aaron Rosenberg Chief Financial Officer 4, 2026-08-05 - Xiaobin Wu President and COO 4, 2026-08-27
- Lai Wang President, Global Head of R&D 4, 2026-06-25
-
Chan Lee Senior Vice President, General Counsel and Corporate Secretary DEF 14A, 2026-04-28 - Titus Ball Chief Accounting Officer 10-K, 2026-02-26
What leadership is saying
“Our strong third quarter results and raised full-year guidance reflect continued rapid global growth and leadership in hematology, anchored by our foundational BTK inhibitor BRUKINSA, which drives powerful and sustained responses in patients, and now joined by our next-generation BCL2 inhibitor BEQALZI. We look forward to multiple catalysts in the coming months from one of the deepest pipelines in oncology, spanning hematology and solid tumors, accelerated by our differentiat”
Earnings press release (8-K Ex. 99.1), filed November 5, 2026
BeOne Medicines Ltd. is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in Basel, Switzerland. It trades as ONC on Nasdaq. Revenue was $5.3B in the fiscal year ending December 31, 2025, +40.2% from the year before. It reported about 12,000 employees. John Oyler is Chief Executive Officer.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $5.3B 10-K, 2026-02-26 | $3.8B 10-K, 2026-02-26 | $2.5B 10-K, 2026-02-26 | $1.4B 10-K, 2025-02-27 | $1.2B 10-K, 2024-02-26 |
| Operating income | $447M 10-K, 2026-02-26 | -$568M 10-K, 2026-02-26 | -$1.2B 10-K, 2026-02-26 | -$1.8B 10-K, 2025-02-27 | -$1.4B 10-K, 2024-02-26 |
| SG&A | $2.1B 10-K, 2026-02-26 | $1.8B 10-K, 2026-02-26 | $1.5B 10-K, 2026-02-26 | $1.3B 10-K, 2025-02-27 | $990M 10-K, 2024-02-26 |
| Net income | $287M 10-K, 2026-02-26 | -$645M 10-K, 2026-02-26 | -$882M 10-K, 2026-02-26 | -$2.0B 10-K, 2025-02-27 | -$1.5B 10-K, 2024-02-26 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| John Oyler | Chief Executive Officer | 4, 2026-08-12 |
| Aaron Rosenberg Chief Financial Officer at BeOne Medicines | Chief Financial Officer | 4, 2026-08-05 |
| Xiaobin Wu Global President and Chief Operating Officer at BeiGene | President and COO | 4, 2026-08-27 |
| Lai Wang | President, Global Head of R&D | 4, 2026-06-25 |
| Chan Lee | Senior Vice President, General Counsel and Corporate Secretary | DEF 14A, 2026-04-28 |
| Titus Ball | Chief Accounting Officer | 10-K, 2026-02-26 |
| Titus B. Ball | Principal Accounting Officer | 4, 2026-09-03 |
| Chan Henry Lee | SVP, General Counsel | 4, 2026-08-13 |
| Alessandro Riva | Director | 10-K, 2026-02-26 |
| Anthony C. Hooper | Director | 10-K, 2026-02-26 |
| Corazon (Corsee) D. Sanders | Director | 10-K, 2026-02-26 |
| Margaret Dugan | Director | 10-K, 2026-02-26 |
| Michael Goller | Director | 10-K, 2026-02-26 |
| Olivier Brandicourt | Director | 10-K, 2026-02-26 |
| Qingqing Yi | Director | 10-K, 2026-02-26 |
| Ranjeev Krishana | Director | 10-K, 2026-02-26 |
What BeOne Medicines Ltd. does
We are a leading global oncology company discovering and developing innovative treatments that are more accessible to cancer patients worldwide.7 million.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 1.48 billion (as of October 30, 2026) | 10-Q, November 5, 2026 |
|---|---|---|
| Public float | $14.7B (as of June 30, 2025) | 10-K, February 26, 2026 |
| Reportable segments | 1 (period ending December 31, 2025) | 10-K, February 26, 2026 |
| Latest proxy statement | Meeting June 11, 2026 (filed April 28, 2026) | DEF 14A, April 28, 2026 |
| Auditor | Ernst & Young LLP (Boston, Massachusetts) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| November 5, 2026 | Chan Henry Lee SVP, General Counsel | Sale | 1,115 | $447K | Form 4, November 9, 2026 |
| October 27, 2026 | Xiaodong Wang Director | Sale | 31,028 | $11.3M | Form 4, October 29, 2026 |
| October 13, 2026 | Xiaodong Wang Director | Sale | 31,027 | $10.9M | Form 4, October 15, 2026 |
| September 30, 2026 | Chan Henry Lee SVP, General Counsel | Sale | 1,115 | $418K | Form 4, October 2, 2026 |
| September 28, 2026 | Xiaodong Wang Director | Sale | 31,028 | $11.3M | Form 4, September 30, 2026 |
| September 8, 2026 | Xiaodong Wang Director | Sale | 38,287 | $13.4M | Form 4, September 10, 2026 |
| September 1, 2026 | Titus B. Ball Principal Accounting Officer | Sale | 132 | $47K | Form 4, September 3, 2026 |
| August 25, 2026 | Xiaobin Wu President and COO | Sale | 280 | $106K | Form 4, August 27, 2026 |
Recent 8-K events
- 8-K filed 2026-11-05
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-08-26
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-08-05
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-06-26
- Item 8.01 Other events
- 8-K filed 2026-06-11
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-05-15
- Item 8.01 Other events
- 8-K filed 2026-05-06
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-04-14
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-02-26
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2025-12-19
- Item 1.02 Termination of a material definitive agreement
Frequently asked questions about BeOne Medicines Ltd.
- What does BeOne Medicines Ltd. do?
- In its own words, from Item 1 of its 10-K: "We are a leading global oncology company discovering and developing innovative treatments that are more accessible to cancer patients worldwide.7 million."
- What is BeOne Medicines Ltd.'s revenue?
- $5.3B for the fiscal year ending December 31, 2025, from its 10-K filed February 26, 2026.
- Is BeOne Medicines Ltd. profitable?
- BeOne Medicines Ltd. reported net income of $287M for the fiscal year ending December 31, 2025.
- How many employees does BeOne Medicines Ltd. have?
- About 12,000 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of BeOne Medicines Ltd.?
- John Oyler, Chief Executive Officer, as named in a 4 filed August 12, 2026.
- Who is the CFO of BeOne Medicines Ltd.?
- Aaron Rosenberg, Chief Financial Officer, as named in a 4 filed August 5, 2026.
- Where is BeOne Medicines Ltd. headquartered?
- Basel, Switzerland.
- What is BeOne Medicines Ltd.'s stock ticker?
- ONC, BEIGF on Nasdaq.
- What industry is BeOne Medicines Ltd. in?
- Pharmaceutical Preparations, SIC code 2834.
- What is BeOne Medicines Ltd.'s website?
- beonemedicines.com.
- When does BeOne Medicines Ltd. report earnings next?
- November 25, 2026. Source: estimate_8k_pattern.
- Is BeOne Medicines Ltd. a public company?
- Yes. BeOne Medicines Ltd. files with the SEC under CIK 0001651308 and trades as ONC.
- Who audits BeOne Medicines Ltd.?
- Ernst & Young LLP, Boston, Massachusetts, as named in its latest annual report (10-K).
- How many shares of BeOne Medicines Ltd. are outstanding?
- 1.48 billion shares as of October 30, 2026, from its 10-Q filed November 5, 2026.
- What is BeOne Medicines Ltd.'s public float?
- $14.7B as of June 30, 2025, as reported on the cover of its 10-K filed February 26, 2026.
- How many business segments does BeOne Medicines Ltd. report?
- 1 reportable segment for the period ending December 31, 2025, from its 10-K filed February 26, 2026.
- When is BeOne Medicines Ltd.'s annual shareholder meeting?
- June 11, 2026, per its proxy statement (DEF 14A) filed April 28, 2026.
- Have BeOne Medicines Ltd. insiders traded stock recently?
- Since July 16, 2026, officers and directors reported 16 open-market sales worth about $243M and 0 purchases on Forms 4 and 5. The most recent: Chan Henry Lee (SVP, General Counsel) sold 1,115 shares on November 5, 2026.